ReP USP - Resultado da busca

Artigo de periodico
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria (2022)
Lau, Leyre Pernaute ; Camara, Mahamadou ; Sousa, Taís Nóbrega de; Morris, Ulrika ; Ferreira, Marcelo Urbano ; Gil, José Pedro
Source: Expert Opinion on Drug Metabolism & Toxicology. Unidade: ICB
Subjects: MICROBIOLOGIA, FARMACOGENÉTICA, MEDICAMENTO, ANTIMALÁRICOS, MALÁRIA FALCIPARUM, PLASMODIUM FALCIPARUM, MALÁRIA, RESISTÊNCIA MICROBIANA ÀS DROGAS, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LAU, Leyre Pernaute et al. An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria. Expert Opinion on Drug Metabolism & Toxicology, v. 18, n. 1, p. 39-59, 2022Tradução . . Disponível em: https://doi.org/10.1080/17425255.2022.2049235. Acesso em: 28 jun. 2024.
APA
Lau, L. P., Camara, M., Sousa, T. N. de, Morris, U., Ferreira, M. U., & Gil, J. P. (2022). An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria. Expert Opinion on Drug Metabolism & Toxicology, 18( 1), 39-59. doi:10.1080/17425255.2022.2049235
NLM
Lau LP, Camara M, Sousa TN de, Morris U, Ferreira MU, Gil JP. An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria [Internet]. Expert Opinion on Drug Metabolism & Toxicology. 2022 ; 18( 1): 39-59.[citado 2024 jun. 28 ] Available from: https://doi.org/10.1080/17425255.2022.2049235
Vancouver
Lau LP, Camara M, Sousa TN de, Morris U, Ferreira MU, Gil JP. An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria [Internet]. Expert Opinion on Drug Metabolism & Toxicology. 2022 ; 18( 1): 39-59.[citado 2024 jun. 28 ] Available from: https://doi.org/10.1080/17425255.2022.2049235
Artigo de periodico
Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia (2022)
Hernandez, Carolina Dagli ; Borges, Jéssica Bassani ; Marçal, Elisangela da Silva Rodrigues; Freitas, Renata Caroline Costa de ; Mori, Augusto Akira ; Gonçalves, Rodrigo Marques; Faludi, André Arpad ; Oliveira, Victor Fernandes de ; Ferreira, Glaucio Monteiro ; Bastos, Gisele Medeiros ; Zhou, Yitian ; Lauschke, Volker Martin ; Cerda, Alvaro ; Hirata, Mario Hiroyuki ; Hirata, Rosario Dominguez Crespo
Source: Pharmaceutics. Unidade: FCF
Subjects: HIPERCOLESTEROLEMIA, ESTATINAS, VARIAÇÃO GENÉTICA, FARMACOGENÉTICA, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HERNANDEZ, Carolina Dagli et al. Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia. Pharmaceutics, v. 14, p. 1-20 art. 944, 2022Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics14050944. Acesso em: 28 jun. 2024.
APA
Hernandez, C. D., Borges, J. B., Marçal, E. da S. R., Freitas, R. C. C. de, Mori, A. A., Gonçalves, R. M., et al. (2022). Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia. Pharmaceutics, 14, 1-20 art. 944. doi:10.3390/pharmaceutics14050944
NLM
Hernandez CD, Borges JB, Marçal E da SR, Freitas RCC de, Mori AA, Gonçalves RM, Faludi AA, Oliveira VF de, Ferreira GM, Bastos GM, Zhou Y, Lauschke VM, Cerda A, Hirata MH, Hirata RDC. Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia [Internet]. Pharmaceutics. 2022 ; 14 1-20 art. 944.[citado 2024 jun. 28 ] Available from: https://doi.org/10.3390/pharmaceutics14050944
Vancouver
Hernandez CD, Borges JB, Marçal E da SR, Freitas RCC de, Mori AA, Gonçalves RM, Faludi AA, Oliveira VF de, Ferreira GM, Bastos GM, Zhou Y, Lauschke VM, Cerda A, Hirata MH, Hirata RDC. Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia [Internet]. Pharmaceutics. 2022 ; 14 1-20 art. 944.[citado 2024 jun. 28 ] Available from: https://doi.org/10.3390/pharmaceutics14050944
Artigo de periodico
Monitoring Plasmodium vivax resistance to antimalarials: persisting challenges and future directions (2021)
Ferreira, Marcelo Urbano ; Sousa, Tais Nobrega de; Rangel, Gabriel W. ; Johansen, Igor Cavallini ; Corder, Rodrigo Malavazi ; Andrade, Simone Ladeia ; Gil, José Pedro
Source: International Journal for Parasitology: Drugs and Drug Resistance. Unidade: ICB
Subjects: PARASITOLOGIA, ANTIMALÁRICOS, PLASMODIUM, INFECÇÕES POR PROTOZOÁRIOS, RESISTÊNCIA MICROBIANA ÀS DROGAS, MARCADOR MOLECULAR, FENÓTIPOS, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERREIRA, Marcelo Urbano et al. Monitoring Plasmodium vivax resistance to antimalarials: persisting challenges and future directions. International Journal for Parasitology: Drugs and Drug Resistance, v. 15, p. 9-24, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.ijpddr.2020.12.001. Acesso em: 28 jun. 2024.
APA
Ferreira, M. U., Sousa, T. N. de, Rangel, G. W., Johansen, I. C., Corder, R. M., Andrade, S. L., & Gil, J. P. (2021). Monitoring Plasmodium vivax resistance to antimalarials: persisting challenges and future directions. International Journal for Parasitology: Drugs and Drug Resistance, 15, 9-24. doi:10.1016/j.ijpddr.2020.12.001
NLM
Ferreira MU, Sousa TN de, Rangel GW, Johansen IC, Corder RM, Andrade SL, Gil JP. Monitoring Plasmodium vivax resistance to antimalarials: persisting challenges and future directions [Internet]. International Journal for Parasitology: Drugs and Drug Resistance. 2021 ; 15 9-24.[citado 2024 jun. 28 ] Available from: https://doi.org/10.1016/j.ijpddr.2020.12.001
Vancouver
Ferreira MU, Sousa TN de, Rangel GW, Johansen IC, Corder RM, Andrade SL, Gil JP. Monitoring Plasmodium vivax resistance to antimalarials: persisting challenges and future directions [Internet]. International Journal for Parasitology: Drugs and Drug Resistance. 2021 ; 15 9-24.[citado 2024 jun. 28 ] Available from: https://doi.org/10.1016/j.ijpddr.2020.12.001
Artigo de periodico
Selenization of S. cerevisiae increases its protective potential in experimental autoimmune encephalomyelitis by triggering an intestinal immunomodulatory loop (2020)
Silva, Thais Fernanda de Campos Fraga ; Mimura, Luiza Ayumi Nishiyama ; Oliveira, Larissa Ragozo Cardoso de ; Toledo, Juliana Helena dos Santos ; Borim, Patrícia Aparecida ; Pezavento, Sofia Fernanda Gonçalvez Zorzella ; Alonso, Diego Peres; Ribolla, Paulo Eduardo Martins ; Oliveira, Carlos Alberto Ferreira de; Fonseca, Denise Morais da ; Villablanca, Eduardo J. ; Sartori, Alexandrina
Source: Scientific Reports. Unidade: ICB
Subjects: IMUNOLOGIA, SACCHAROMYCES, ESCLEROSE MÚLTIPLA, DOENÇAS AUTOIMUNES, SISTEMA NERVOSO CENTRAL, MEDICAMENTO, CAMUNDONGOS, LINFONODOS DE ANIMAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Thais Fernanda de Campos Fraga et al. Selenization of S. cerevisiae increases its protective potential in experimental autoimmune encephalomyelitis by triggering an intestinal immunomodulatory loop. Scientific Reports, v. 10, p. 17 , 2020Tradução . . Disponível em: https://doi.org/10.1038/s41598-020-79102-7. Acesso em: 28 jun. 2024.
APA
Silva, T. F. de C. F., Mimura, L. A. N., Oliveira, L. R. C. de, Toledo, J. H. dos S., Borim, P. A., Pezavento, S. F. G. Z., et al. (2020). Selenization of S. cerevisiae increases its protective potential in experimental autoimmune encephalomyelitis by triggering an intestinal immunomodulatory loop. Scientific Reports, 10, 17 . doi:10.1038/s41598-020-79102-7
NLM
Silva TF de CF, Mimura LAN, Oliveira LRC de, Toledo JH dos S, Borim PA, Pezavento SFGZ, Alonso DP, Ribolla PEM, Oliveira CAF de, Fonseca DM da, Villablanca EJ, Sartori A. Selenization of S. cerevisiae increases its protective potential in experimental autoimmune encephalomyelitis by triggering an intestinal immunomodulatory loop [Internet]. Scientific Reports. 2020 ; 10 17 .[citado 2024 jun. 28 ] Available from: https://doi.org/10.1038/s41598-020-79102-7
Vancouver
Silva TF de CF, Mimura LAN, Oliveira LRC de, Toledo JH dos S, Borim PA, Pezavento SFGZ, Alonso DP, Ribolla PEM, Oliveira CAF de, Fonseca DM da, Villablanca EJ, Sartori A. Selenization of S. cerevisiae increases its protective potential in experimental autoimmune encephalomyelitis by triggering an intestinal immunomodulatory loop [Internet]. Scientific Reports. 2020 ; 10 17 .[citado 2024 jun. 28 ] Available from: https://doi.org/10.1038/s41598-020-79102-7
Artigo de periodico
Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids (2020)
Costa, Soraia Katia Pereira ; Muscará, Marcelo Nicolás (Orientador) ; Allain, Thibault ; Dallazen, Jorge Luiz ; Santos, Larissa Gonzaga ; Buret, Andre G.; Vaughan, David J.; Fowler, Christopher J.; De Nucci, Gilberto ; Wallace, John L.
Source: Antioxidants & Redox Signaling. Unidade: ICB
Subjects: FARMACOLOGIA, ANALGÉSICOS, INFLAMAÇÃO, DOR, ÚLCERA GÁSTRICA, SISTEMA GASTROINTESTINAL, ANTI-INFLAMATÓRIOS NÃO ESTEROIDES, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COSTA, Soraia Katia Pereira et al. Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids. Antioxidants & Redox Signaling, p. 7 , 2020Tradução . . Disponível em: https://doi.org/10.1089/ars.2019.7884. Acesso em: 28 jun. 2024.
APA
Costa, S. K. P., Allain, T., Dallazen, J. L., Santos, L. G., Buret, A. G., Vaughan, D. J., et al. (2020). Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids. Antioxidants & Redox Signaling, 7 . doi:10.1089/ars.2019.7884
NLM
Costa SKP, Allain T, Dallazen JL, Santos LG, Buret AG, Vaughan DJ, Fowler CJ, De Nucci G, Wallace JL. Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids [Internet]. Antioxidants & Redox Signaling. 2020 ;7 .[citado 2024 jun. 28 ] Available from: https://doi.org/10.1089/ars.2019.7884
Vancouver
Costa SKP, Allain T, Dallazen JL, Santos LG, Buret AG, Vaughan DJ, Fowler CJ, De Nucci G, Wallace JL. Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids [Internet]. Antioxidants & Redox Signaling. 2020 ;7 .[citado 2024 jun. 28 ] Available from: https://doi.org/10.1089/ars.2019.7884

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Funding Agencies

Non normalized affiliation

Countries of institutions of collaboration